Levi & Korsinsky, LLP | Securities Class Action Attorneys

53

Days Left

FLYE

Fly-E Group, Inc.

Deadline

November 10 2025

Class Period

7/15/25 - 8/14/25

Allegations

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the safety of Fly-E’s lithium battery which in turn took a material toll on its E-vehicle sales revenue, despite making lofty long-term projections, Fly-E’s forecasting processes fell short as sales continued to decline and operating expenses increased, ultimately, derailing the Company’s revenue projections. On August 14, 2025, the truth emerged when Fly-E filed a form NT 10-Q: Notification of inability to timely file Form 10-Q for the first quarter of fiscal year 2026 revealing a substantial decrease of 32% in net revenues “primarily driven by a decrease in total units sold.” In pertinent part, the Company attributed the decline to “recent lithium-battery accidents involving E-Bikes and E-Scooters.” Following this news, the price of Fly E’s common stock declined dramatically. From a closing market price of $7.76 per share on August 14, 2025, Fly-E’s stock price fell to $1.00 per share on August 15, 2025, a decline of about 87% in the span of just a single day.

Class Period

7/15/25 - 8/14/25

Deadline

November 10 2025

Learn More

55

Days Left

VFC

V.F. Corporation

Deadline

November 12 2025

Class Period

10/30/23 - 5/20/25

Allegations

According to the complaint, defendants disseminated materially false and misleading statements and/or concealed material adverse facts concerning the true state of VFC’s turnaround plans; notably, that additional significant reset actions would be necessary to return the Vans brand to growth, resulting in significant setbacks to Vans’ revenue growth trajectory. The truth emerged on May 21, 2025, when VFC reported its fourth quarter and full-year fiscal 2025 results, highlighting a significant decline in Vans’ growth trajectory, which faltered from an 8% loss the quarter before to a 20% loss in the fourth quarter, and noting such decline would continue through the next quarter. The Company attributed its results and below-expectation guidance largely as “a direct effect of deliberately reduced revenue to eliminate unprofitable or unproductive businesses” and “an additional set of deliberate actions” already in-place but previously unannounced. VFC further noted that, disregarding these deliberate actions, Vans would still have shown a “high single digit[]” revenue decline, suggesting growth slowed in comparison to the prior years’ sequential improvements irrespective of management’s new “deliberate actions.” On this news, the price of VFC’s common stock declined dramatically. From a closing market price of $14.43 per share on May 20, 2025, VFC’s stock price fell to $12.15 per share on May 21, 2025, a decline of about 15.8% in the span of just a single day.

Class Period

10/30/23 - 5/20/25

Deadline

November 12 2025

Learn More

60

Days Left

CYTK

Cytokinetics, Incorporated

Deadline

November 17 2025

Class Period

12/27/23 - 5/6/25

Allegations

According to the complaint, defendants made materially false and misleading statements regarding the timeline for the New Drug Application (“NDA”) submission and approval process for aficamten. Specifically, defendants represented that the Company expected approval from the U.S. Food and Drug Administration (“FDA”) for its NDA for aficamten in the second half of 2025, based on a September 26, 2025 PDUFA date, and failed to disclose material risks related to the Company’s failure to submit a Risk Evaluation and Mitigation Strategy (“REMS”) that could delay the regulatory process. On May 6, 2025, during an earnings call, it was revealed that the Company had multiple pre-NDA meetings with the FDA discussing safety monitoring and risk mitigation but chose to submit the NDA without a REMS, relying on labeling and voluntary education materials. This confirmed defendants’ awareness of potential REMS requirements and their reckless decision to omit it from the initial submission, misleading investors about the regulatory timeline. As a result of defendants’ false and misleading statements, class members purchased Cytokinetics’ common stock at artificially inflated prices and suffered significant losses when the truth was revealed.

Class Period

12/27/23 - 5/6/25

Deadline

November 17 2025

Learn More

1

Days Left

ANRO

Alto Neuroscience, Inc.

Deadline

September 19 2025

Class Period

This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (a) Alto common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about February 2, 2024; and/or (b) Alto securities between February 2, 2024 and October 22, 2024, both dates inclusive.

Allegations

(i) The Company’s product pipeline, ALTO-100, was less effective in treating major depressive disorder than defendants had led investors to believe; (ii) accordingly, ALTO-100’s clinical, regulatory, and commercial prospects were overstated; (iii) as a result, Alto’s business and/or financial prospects were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (a) Alto common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about February 2, 2024; and/or (b) Alto securities between February 2, 2024 and October 22, 2024, both dates inclusive.

Deadline

September 19 2025

Learn More

4

Days Left

REPL

Replimune Group, Inc.

Deadline

September 22 2025

Class Period

11/22/24 - 7/21/25

Allegations

(1) defendants recklessly overstated the IGNYTE trial’s prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, defendants’ statements about Replimune’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

11/22/24 - 7/21/25

Deadline

September 22 2025

Learn More

4

Days Left

FI

Fiserv, Inc.

Deadline

September 22 2025

Class Period

7/24/24 - 7/22/25

Allegations

(a) Due to cost issues and other problems with its older point-of-sale platform, Payeezy, Fiserv forced Payeezy merchants to convert to its Clover platform; (b) Clover’s revenue growth and GPV growth were temporarily boosted by these conversions, which concealed a slowdown in new merchant business; (c) shortly after these conversions, a significant portion of former Payeezy merchants switched to competing solutions due to Clover’s high pricing, inadequate customer service, and other issues; (d) as a result of these merchant losses, Clover’s GPV growth was significantly slowing, and its revenue growth was unsustainable; and (e) based on the foregoing, Fiserv’s positive class period statements about Clover growth strategies, competition, attrition, GPV growth, and business prospects were materially false and misleading.

Class Period

7/24/24 - 7/22/25

Deadline

September 22 2025

Learn More

4

Days Left

RXST

RxSight, Inc.

Deadline

September 22 2025

Class Period

5/7/24 - 7/8/25

Allegations

(1) the Company was experiencing “adoption challenges” and/or structural issues resulting in declines in sales and utilization; (2) defendants had overstated the demand for RxSight’s products; (3) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025; and (4) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

5/7/24 - 7/8/25

Deadline

September 22 2025

Learn More

5

Days Left

FLYW

Flywire Corporation

Deadline

September 23 2025

Class Period

2/28/24 - 2/25/25

Allegations

(i) the strength and sustainability of Flywire’s revenue growth was overstated; (ii) the negative impact that permit- and visa-related restrictions were having and were likely to have on Flywire’s business was understated; and (iii) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

2/28/24 - 2/25/25

Deadline

September 23 2025

Learn More

8

Days Left

SOC

Sable Offshore Corp.

Deadline

September 26 2025

Class Period

This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded Sable Offshore securities between May 19, 2025 and June 3, 2025, inclusive, and/or pursuant and/or traceable to the Company’s May 21, 2025 secondary public offering.

Allegations

(1) defendants represented that Sable Offshore Corp. had restarted oil production off the coast of California when it had not; and (2) as a result, defendants statements about Sables business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Class Period

This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded Sable Offshore securities between May 19, 2025 and June 3, 2025, inclusive, and/or pursuant and/or traceable to the Company’s May 21, 2025 secondary public offering.

Deadline

September 26 2025

Learn More

8

Days Left

LMT

Lockheed Martin Corporation

Deadline

September 26 2025

Class Period

1/23/24 - 7/21/25

Allegations

(1) Lockheed Martin lacked effective internal controls regarding its purportedly risk adjusted contracts including the reporting of its risk adjusted profit booking rate; (2) Lockheed Martin lacked effective procedures to perform reasonably accurate comprehensive reviews of program requirements, technical complexities, schedule, and risks; (3) Lockheed Martin overstated its ability to deliver on its contract commitments in terms of cost, quality and schedule; (4) as a result, the Company was reasonably likely to report significant losses; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

1/23/24 - 7/21/25

Deadline

September 26 2025

Learn More

12

Days Left

NVO

Novo Nordisk A/S

Deadline

September 30 2025

Class Period

5/7/25 - 7/28/25

Allegations

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Novo’s growth potential; notably, that its asserted potential to capitalize on the compounded market greatly understated the potential impact of the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood such patients would switch to Novo’s branded alternatives, and further greatly overstated the potential GLP-1 market or otherwise Novo’s capability to penetrate said markets to achieve continued growth. On July 29, 2025, Novo announced it was lowering its sales and profit outlook ahead of reporting its results for the second quarter of fiscal year 2025. The Company attributed the guide down on “lowered growth expectations for the second half of 2025” for both Wegovy and Ozempic due to “the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition.” Following this news, the price of Novo’s common stock declined dramatically. From a closing market price of $69.00 per share on July 28, 2025, Novo’s stock price fell to $53.94 per share on July 29, 2025, a decline of about 21.83% in the span of just a single day.

Class Period

5/7/25 - 7/28/25

Deadline

September 30 2025

Learn More

12

Days Left

LINE

Lineage, Inc.

Deadline

September 30 2025

Class Period

This lawsuit is on behalf of all purchasers of Lineage common stock in or traceable to the registration statement used in connection with the Company’s July 26, 2024 initial public offering.

Allegations

(a) Lineage was then experiencing sustained weakening in customer demand, as additional cold-storage supply had come on line, the Company’s customers destocked a glut of excessive inventory built up during the COVID-19 pandemic, and the Company’s customers shifted to maintaining leaner cold-storage inventories on a go-forward basis in response to changed consumer trends; (b) Lineage had implemented price increases in the lead-up to the IPO that could not be sustained in light of the weakening demand environment facing the Company; (c) Lineage was unable to effectively counteract the adverse trends listed in (a)-(b) above through the use of minimum storage guarantees or as a result of operational efficiencies, technological improvements, or its purported competitive advantages; (d) that, as a result of (a)-(c) above, rather than enjoying stable revenue growth, high occupancy rates, and steady rent escalation as represented in the registration statement, Lineage was in fact suffering from stagnant or falling revenue, occupancy rates, and rent prices; and (e) that, as a result of (a)-(d) above, Lineage’s financial results, business operations, and prospects were materially impaired.

Class Period

This lawsuit is on behalf of all purchasers of Lineage common stock in or traceable to the registration statement used in connection with the Company’s July 26, 2024 initial public offering.

Deadline

September 30 2025

Learn More

15

Days Left

TSLA

Tesla, Inc.

Deadline

October 3 2025

Class Period

4/19/23 - 6/22/25

Allegations

(i) Tesla overstated the effectiveness of its autonomous driving technology; (ii) there was thus a significant risk that the Company’s autonomous driving vehicles, including the Robotaxi, would operate dangerously and/or in violation of traffic laws; (iii) the foregoing increased the likelihood that Tesla would become subject to heightened regulatory scrutiny; (iv) accordingly, Tesla’s business and/or financial prospects were overstated; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times

Class Period

4/19/23 - 6/22/25

Deadline

October 3 2025

Learn More

18

Days Left

ALT

Altimmune, Inc.

Deadline

October 6 2025

Class Period

8/10/23 - 6/25/25

Allegations

According to the complaint, on June 26, 2025, Altimmune published a press release announcing topline results from the IMPACT Phase 2b MASH trial of Pemvidutide in the Treatment of MASH. While defendants had continuously provided inflated expectations ahead of these results, the analysis showed a pointed failure by the Company to achieve statistical significance in its analysis of the fibrosis reduction primary endpoint in its IMPACT Phase 2b MASH trial. In particular, while a positive trend in fibrosis improvement was observed, statistical significance was not met due to a higher-than-expected placebo response. When questioned about this concerning miss, defendants answered indifferently, attributing this result to the Phase 2 nature of the trial and stated that Altimmune was hoping for better results following the Phase 3 trial. Following this news, the price of Altimmune’s common stock declined dramatically. From a closing market price of $7.71 per share on June 25, 2025, Altimmune’s stock price fell to $3.61 per share on June 26, 2025, a decline of 53.2% in the span of just a single day.

Class Period

8/10/23 - 6/25/25

Deadline

October 6 2025

Learn More

26

Days Left

KLC

KinderCare Learning Companies, Inc.

Deadline

October 14 2025

Class Period

This lawsuit is on behalf of all purchasers of KinderCare common stock in or traceable to the Company’s October 2024 initial public offering

Allegations

(a) numerous incidents of child abuse, neglect, and harm had occurred at KinderCare facilities; (b) KinderCare did not provide the “highest quality care possible” at its facilities, and, indeed, in numerous instances had failed to provide even basic care, meet minimum standards in the child care industry, or comply with the laws and regulations governing the care of children; and (c) as a result of (a)-(b) above, KinderCare was exposed to a material, undisclosed risk of lawsuits, adverse regulatory action, negative publicity, reputational damage, and business loss.

Class Period

This lawsuit is on behalf of all purchasers of KinderCare common stock in or traceable to the Company’s October 2024 initial public offering

Deadline

October 14 2025

Learn More

26

Days Left

UNCY

Unicycive Therapeutics, Inc.

Deadline

October 14 2025

Class Period

3/29/24 - 6/27/25

Allegations

(i) Unicycive’s readiness and ability to satisfy the FDA’s manufacturing compliance requirements was overstated; (ii) the oxylanthanum carbonate new drug application’s regulatory prospects were likewise overstated; and (iii) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

3/29/24 - 6/27/25

Deadline

October 14 2025

Learn More

26

Days Left

CHTR

Charter Communications, Inc.

Deadline

October 14 2025

Class Period

This lawsuit is on behalf of all persons and entities who purchased or otherwise acquired Charter securities, purchased call options on Charter common stock, or sold put options on Charter common stock, between July 26, 2024, and July 24, 2025, inclusive.

Allegations

(i) the impact of the Affordable Connectivity Program (ACP) end was a material event the Company was unable to manage or promptly move beyond; (ii) the ACP end was actually having a sustaining impact on Internet customer declines and revenue; (iii) neither was the Company executing broader operations in a way that would compensate for, or overcome the impact, of the ACP ending; (iv) the Internet customer declines and broader failure of Charter’s execution strategy created much greater risks on business plans and earnings growth than reported; (v) accordingly, the Company had no reasonable basis to state the Company was successfully executing operations, managing causes of Internet customer declines, or provide overly optimistic statements about the long term trajectory of the Company and EBITDA growth; and (iv) as a result of the foregoing, defendants materially misled with, and/or lacked a reasonable basis for, their positive statements about the Company’s business, operations, outlook during the Class Period.

Class Period

This lawsuit is on behalf of all persons and entities who purchased or otherwise acquired Charter securities, purchased call options on Charter common stock, or sold put options on Charter common stock, between July 26, 2024, and July 24, 2025, inclusive.

Deadline

October 14 2025

Learn More

32

Days Left

SNAP

Snap Inc.

Deadline

October 20 2025

Class Period

4/29/25 - 8/5/25

Allegations

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Snap’s advertising revenue growth rate; notably, that, due to Snap’s own execution failure, it had significantly declined from 9% in the first quarter to only 1% in April. On August 5, 2025, Snap announced its financial results for the second quarter of fiscal 2025, disclosing a deceleration in advertising revenue growth. The Company attributed the slowdown to “an issue related to our ad platform, the timing of Ramadan and the effects of the de minimis changes.” Following this news, the price of Snap’s common stock declined dramatically. From a closing market price of $9.39 per share on August 5, 2025, Snap’s stock price fell to $7.78 per share on August 6, 2025, a decline of about 17.15% in the span of just a single day.

Class Period

4/29/25 - 8/5/25

Deadline

October 20 2025

Learn More

32

Days Left

PUBM

PubMatic, Inc.

Deadline

October 20 2025

Class Period

2/27/25 - 8/11/25

Allegations

(1) a top demand side platform buyer was shifting a significant number of clients to a new platform which evaluated inventory differently; (2) as a result, PubMatic was seeing a reduction in ad spend and revenue from this top demand side platform buyer; and (3) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

2/27/25 - 8/11/25

Deadline

October 20 2025

Learn More

33

Days Left

AI

C3.ai, Inc.

Deadline

October 21 2025

Class Period

2/26/25 - 8/8/25

Allegations

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of C3 AI’s growth; notably, that its Chief Executive Officer health was having a significant impact on the Company’s ability to close deals, that its management was unable or otherwise ineffectual in minimizing that impact, and that C3 AI would not be able to execute upon its profit and growth potential as a result. On August 8, 2025, C3 AI announced disappointing preliminary financial results for the first quarter of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026. The Company attributed its poor sales results and lowered guidance on “the reorganization with new leadership” and the health ailments of its Chief Executive Officer. Following this news, the price of C3 AI’s common stock declined dramatically. From a closing market price of $22.13 per share on August 8, 2025, C3 AI’s stock price fell to $16.47 per share on August 11, 2025, a decline of about 25.58% in the span of just a single day.

Class Period

2/26/25 - 8/8/25

Deadline

October 21 2025

Learn More

33

Days Left

NUTX

Nutex Health Inc.

Deadline

October 21 2025

Class Period

8/8/24 - 8/14/25

Allegations

(i) HaloMD, a third-party IDR vendor, was achieving lucrative arbitration results for Nutex by engaging in a coordinated scheme to defraud insurance companies; (ii) as a result, to the extent that they were the product of fraudulent conduct, revenues attributable to the Company’s engagement with HaloMD in the IDR process were unsustainable; (iii) in addition, the Company overstated the extent to which it had remediated, and/or its ability to remediate, the material weaknesses in its internal controls over financial reporting; (iv) as a result, the Company was unable to effectively account for the treatment of certain of its stock based compensation obligations; (v) as a result, Nutex improperly calculated these stock based compensation obligations as equity rather than liabilities; (vi) the foregoing increased the risk that the Company would be unable to timely file certain financial reports with the SEC; (vii) accordingly, Nutex’s business and/or financial prospects were overstated; and (viii) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

8/8/24 - 8/14/25

Deadline

October 21 2025

Learn More

37

Days Left

LFMD

LifeMD, Inc.

Deadline

October 25 2025

Class Period

5/7/25 - 8/5/25

Allegations

(1) defendants materially overstated LifeMD’s competitive position; (2) defendants were reckless in raising LifeMD’s 2025 guidance, considering that they had not properly accounted for rising customer acquisition costs in LifeMD’s RexMD segment, as well as for customer acquisition costs related to the sale of drugs designed to treat obesity, including Wegovy and Zepbound; and (3) as a result, defendants’ statements about LifeMD’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

5/7/25 - 8/5/25

Deadline

October 25 2025

Learn More

40

Days Left

DOW

Dow Inc.

Deadline

October 28 2025

Class Period

1/30/25 - 7/23/25

Allegations

(i) Dow’s ability to mitigate macroeconomic and tariff-related headwinds, as well as to maintain the financial flexibility needed to support its lucrative dividend, was overstated; (ii) the true scope and severity of the foregoing headwinds’ negative impacts on Dow’s business and financial condition was understated, particularly with respect to competitive and pricing pressures, softening global sales and demand for the Company’s products, and an oversupply of products in the Company’s global markets; and (iii) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

1/30/25 - 7/23/25

Deadline

October 28 2025

Learn More

40

Days Left

SMLR

Semler Scientific, Inc.

Deadline

October 28 2025

Class Period

3/10/21 - 4/15/25

Allegations

(1) Semler Scientific did not disclose a material investigation by the United States Department of Justice into violations of the False Claims Act, while discussing possible violations of the False Claims Act in hypothetical terms; and (2) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.

Class Period

3/10/21 - 4/15/25

Deadline

October 28 2025

Learn More

46

Days Left

TROX

Tronox Holdings plc

Deadline

November 3 2025

Class Period

2/12/25 - 7/30/25

Allegations

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Tronox’s ability to forecast the demand for its pigment and zircon products or otherwise the true state of its commercial division, despite making lofty long-term projections, Tronox’s forecasting processes fell short as sales continued to decline and costs increased, ultimately, derailing the Company’s revenue projections. On July 30, 2025, Tronox announced its financial results for the second quarter of fiscal 2025, revealing a significant reduction in TiO2 sales for the quarter. The Company attributed the decline to “softer than anticipated coatings season and heightened competitive dynamics.” As a result of the setback in sales, defendants revised the Company’s 2025 financial outlook lowering its full-year revenue guidance and reducing its dividend by 60%. Following this news, Tronox’s common stock declined dramatically. From a closing market price of $5.14 per share on July 30, 2025, Tronox’s stock price fell to $3.19 per share on July 31, 2025, a decline of about 38% in the span of just a single day.

Class Period

2/12/25 - 7/30/25

Deadline

November 3 2025

Learn More

50

Days Left

SVRA

Savara Inc.

Deadline

November 7 2025

Class Period

3/4/24 - 5/23/25

Allegations

(i) MOLBREEVI BLA, the treatment of pulmonary alveolar proteinosis, lacked sufficient information regarding MOLBREEVI’s chemistry, manufacturing, and/or controls; (ii) accordingly, FDA was unlikely to approve the MOLBREEVI BLA in its current form; (iii) foregoing made it unlikely that Savara would complete its submission of the MOLBREEVI BLA within the timeframe it had represented to investors; (iv) delay in MOLBREEVI’s regulatory approval increased the likelihood that the Company would need to raise additional capital; and (v) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

3/4/24 - 5/23/25

Deadline

November 7 2025

Learn More

53

Days Left

LNTH

Lantheus Holdings, Inc.

Deadline

November 10 2025

Class Period

2/26/25 - 8/5/25

Allegations

According to the filed complaint, defendants made false statements and/or concealed that: defendants created the false impression that they possessed reliable information pertaining to the Company’s projected revenue outlook and anticipated growth while also minimizing risk from competition and pricing dynamics, seasonality, and macroeconomic fluctuations. In truth, Lantheus’ optimistic reports of Pylarify’s sales growth potential and pricing normalization fell short of reality; Lantheus, despite defendants claims, did not have an accurate understanding of the pricing and competitive dynamics of Pylarify’s market.

Class Period

2/26/25 - 8/5/25

Deadline

November 10 2025

Learn More

53

Days Left

FLYE

Fly-E Group, Inc.

Deadline

November 10 2025

Class Period

7/15/25 - 8/14/25

Allegations

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the safety of Fly-E’s lithium battery which in turn took a material toll on its E-vehicle sales revenue, despite making lofty long-term projections, Fly-E’s forecasting processes fell short as sales continued to decline and operating expenses increased, ultimately, derailing the Company’s revenue projections. On August 14, 2025, the truth emerged when Fly-E filed a form NT 10-Q: Notification of inability to timely file Form 10-Q for the first quarter of fiscal year 2026 revealing a substantial decrease of 32% in net revenues “primarily driven by a decrease in total units sold.” In pertinent part, the Company attributed the decline to “recent lithium-battery accidents involving E-Bikes and E-Scooters.” Following this news, the price of Fly E’s common stock declined dramatically. From a closing market price of $7.76 per share on August 14, 2025, Fly-E’s stock price fell to $1.00 per share on August 15, 2025, a decline of about 87% in the span of just a single day.

Class Period

7/15/25 - 8/14/25

Deadline

November 10 2025

Learn More

55

Days Left

VFC

V.F. Corporation

Deadline

November 12 2025

Class Period

10/30/23 - 5/20/25

Allegations

According to the complaint, defendants disseminated materially false and misleading statements and/or concealed material adverse facts concerning the true state of VFC’s turnaround plans; notably, that additional significant reset actions would be necessary to return the Vans brand to growth, resulting in significant setbacks to Vans’ revenue growth trajectory. The truth emerged on May 21, 2025, when VFC reported its fourth quarter and full-year fiscal 2025 results, highlighting a significant decline in Vans’ growth trajectory, which faltered from an 8% loss the quarter before to a 20% loss in the fourth quarter, and noting such decline would continue through the next quarter. The Company attributed its results and below-expectation guidance largely as “a direct effect of deliberately reduced revenue to eliminate unprofitable or unproductive businesses” and “an additional set of deliberate actions” already in-place but previously unannounced. VFC further noted that, disregarding these deliberate actions, Vans would still have shown a “high single digit[]” revenue decline, suggesting growth slowed in comparison to the prior years’ sequential improvements irrespective of management’s new “deliberate actions.” On this news, the price of VFC’s common stock declined dramatically. From a closing market price of $14.43 per share on May 20, 2025, VFC’s stock price fell to $12.15 per share on May 21, 2025, a decline of about 15.8% in the span of just a single day.

Class Period

10/30/23 - 5/20/25

Deadline

November 12 2025

Learn More

60

Days Left

CYTK

Cytokinetics, Incorporated

Deadline

November 17 2025

Class Period

12/27/23 - 5/6/25

Allegations

According to the complaint, defendants made materially false and misleading statements regarding the timeline for the New Drug Application (“NDA”) submission and approval process for aficamten. Specifically, defendants represented that the Company expected approval from the U.S. Food and Drug Administration (“FDA”) for its NDA for aficamten in the second half of 2025, based on a September 26, 2025 PDUFA date, and failed to disclose material risks related to the Company’s failure to submit a Risk Evaluation and Mitigation Strategy (“REMS”) that could delay the regulatory process. On May 6, 2025, during an earnings call, it was revealed that the Company had multiple pre-NDA meetings with the FDA discussing safety monitoring and risk mitigation but chose to submit the NDA without a REMS, relying on labeling and voluntary education materials. This confirmed defendants’ awareness of potential REMS requirements and their reckless decision to omit it from the initial submission, misleading investors about the regulatory timeline. As a result of defendants’ false and misleading statements, class members purchased Cytokinetics’ common stock at artificially inflated prices and suffered significant losses when the truth was revealed.

Class Period

12/27/23 - 5/6/25

Deadline

November 17 2025

Learn More

1

Days Left

ANRO

Alto Neuroscience, Inc.

Deadline

September 19 2025

Class Period

This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (a) Alto common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about February 2, 2024; and/or (b) Alto securities between February 2, 2024 and October 22, 2024, both dates inclusive.

Allegations

(i) The Company’s product pipeline, ALTO-100, was less effective in treating major depressive disorder than defendants had led investors to believe; (ii) accordingly, ALTO-100’s clinical, regulatory, and commercial prospects were overstated; (iii) as a result, Alto’s business and/or financial prospects were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (a) Alto common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about February 2, 2024; and/or (b) Alto securities between February 2, 2024 and October 22, 2024, both dates inclusive.

Deadline

September 19 2025

Learn More

4

Days Left

REPL

Replimune Group, Inc.

Deadline

September 22 2025

Class Period

11/22/24 - 7/21/25

Allegations

(1) defendants recklessly overstated the IGNYTE trial’s prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, defendants’ statements about Replimune’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

11/22/24 - 7/21/25

Deadline

September 22 2025

Learn More

4

Days Left

FI

Fiserv, Inc.

Deadline

September 22 2025

Class Period

7/24/24 - 7/22/25

Allegations

(a) Due to cost issues and other problems with its older point-of-sale platform, Payeezy, Fiserv forced Payeezy merchants to convert to its Clover platform; (b) Clover’s revenue growth and GPV growth were temporarily boosted by these conversions, which concealed a slowdown in new merchant business; (c) shortly after these conversions, a significant portion of former Payeezy merchants switched to competing solutions due to Clover’s high pricing, inadequate customer service, and other issues; (d) as a result of these merchant losses, Clover’s GPV growth was significantly slowing, and its revenue growth was unsustainable; and (e) based on the foregoing, Fiserv’s positive class period statements about Clover growth strategies, competition, attrition, GPV growth, and business prospects were materially false and misleading.

Class Period

7/24/24 - 7/22/25

Deadline

September 22 2025

Learn More

4

Days Left

RXST

RxSight, Inc.

Deadline

September 22 2025

Class Period

5/7/24 - 7/8/25

Allegations

(1) the Company was experiencing “adoption challenges” and/or structural issues resulting in declines in sales and utilization; (2) defendants had overstated the demand for RxSight’s products; (3) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025; and (4) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

5/7/24 - 7/8/25

Deadline

September 22 2025

Learn More

5

Days Left

FLYW

Flywire Corporation

Deadline

September 23 2025

Class Period

2/28/24 - 2/25/25

Allegations

(i) the strength and sustainability of Flywire’s revenue growth was overstated; (ii) the negative impact that permit- and visa-related restrictions were having and were likely to have on Flywire’s business was understated; and (iii) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

2/28/24 - 2/25/25

Deadline

September 23 2025

Learn More

8

Days Left

SOC

Sable Offshore Corp.

Deadline

September 26 2025

Class Period

This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded Sable Offshore securities between May 19, 2025 and June 3, 2025, inclusive, and/or pursuant and/or traceable to the Company’s May 21, 2025 secondary public offering.

Allegations

(1) defendants represented that Sable Offshore Corp. had restarted oil production off the coast of California when it had not; and (2) as a result, defendants statements about Sables business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Class Period

This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded Sable Offshore securities between May 19, 2025 and June 3, 2025, inclusive, and/or pursuant and/or traceable to the Company’s May 21, 2025 secondary public offering.

Deadline

September 26 2025

Learn More

8

Days Left

LMT

Lockheed Martin Corporation

Deadline

September 26 2025

Class Period

1/23/24 - 7/21/25

Allegations

(1) Lockheed Martin lacked effective internal controls regarding its purportedly risk adjusted contracts including the reporting of its risk adjusted profit booking rate; (2) Lockheed Martin lacked effective procedures to perform reasonably accurate comprehensive reviews of program requirements, technical complexities, schedule, and risks; (3) Lockheed Martin overstated its ability to deliver on its contract commitments in terms of cost, quality and schedule; (4) as a result, the Company was reasonably likely to report significant losses; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

1/23/24 - 7/21/25

Deadline

September 26 2025

Learn More

12

Days Left

NVO

Novo Nordisk A/S

Deadline

September 30 2025

Class Period

5/7/25 - 7/28/25

Allegations

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Novo’s growth potential; notably, that its asserted potential to capitalize on the compounded market greatly understated the potential impact of the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood such patients would switch to Novo’s branded alternatives, and further greatly overstated the potential GLP-1 market or otherwise Novo’s capability to penetrate said markets to achieve continued growth. On July 29, 2025, Novo announced it was lowering its sales and profit outlook ahead of reporting its results for the second quarter of fiscal year 2025. The Company attributed the guide down on “lowered growth expectations for the second half of 2025” for both Wegovy and Ozempic due to “the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition.” Following this news, the price of Novo’s common stock declined dramatically. From a closing market price of $69.00 per share on July 28, 2025, Novo’s stock price fell to $53.94 per share on July 29, 2025, a decline of about 21.83% in the span of just a single day.

Class Period

5/7/25 - 7/28/25

Deadline

September 30 2025

Learn More

12

Days Left

LINE

Lineage, Inc.

Deadline

September 30 2025

Class Period

This lawsuit is on behalf of all purchasers of Lineage common stock in or traceable to the registration statement used in connection with the Company’s July 26, 2024 initial public offering.

Allegations

(a) Lineage was then experiencing sustained weakening in customer demand, as additional cold-storage supply had come on line, the Company’s customers destocked a glut of excessive inventory built up during the COVID-19 pandemic, and the Company’s customers shifted to maintaining leaner cold-storage inventories on a go-forward basis in response to changed consumer trends; (b) Lineage had implemented price increases in the lead-up to the IPO that could not be sustained in light of the weakening demand environment facing the Company; (c) Lineage was unable to effectively counteract the adverse trends listed in (a)-(b) above through the use of minimum storage guarantees or as a result of operational efficiencies, technological improvements, or its purported competitive advantages; (d) that, as a result of (a)-(c) above, rather than enjoying stable revenue growth, high occupancy rates, and steady rent escalation as represented in the registration statement, Lineage was in fact suffering from stagnant or falling revenue, occupancy rates, and rent prices; and (e) that, as a result of (a)-(d) above, Lineage’s financial results, business operations, and prospects were materially impaired.

Class Period

This lawsuit is on behalf of all purchasers of Lineage common stock in or traceable to the registration statement used in connection with the Company’s July 26, 2024 initial public offering.

Deadline

September 30 2025

Learn More

15

Days Left

TSLA

Tesla, Inc.

Deadline

October 3 2025

Class Period

4/19/23 - 6/22/25

Allegations

(i) Tesla overstated the effectiveness of its autonomous driving technology; (ii) there was thus a significant risk that the Company’s autonomous driving vehicles, including the Robotaxi, would operate dangerously and/or in violation of traffic laws; (iii) the foregoing increased the likelihood that Tesla would become subject to heightened regulatory scrutiny; (iv) accordingly, Tesla’s business and/or financial prospects were overstated; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times

Class Period

4/19/23 - 6/22/25

Deadline

October 3 2025

Learn More

18

Days Left

ALT

Altimmune, Inc.

Deadline

October 6 2025

Class Period

8/10/23 - 6/25/25

Allegations

According to the complaint, on June 26, 2025, Altimmune published a press release announcing topline results from the IMPACT Phase 2b MASH trial of Pemvidutide in the Treatment of MASH. While defendants had continuously provided inflated expectations ahead of these results, the analysis showed a pointed failure by the Company to achieve statistical significance in its analysis of the fibrosis reduction primary endpoint in its IMPACT Phase 2b MASH trial. In particular, while a positive trend in fibrosis improvement was observed, statistical significance was not met due to a higher-than-expected placebo response. When questioned about this concerning miss, defendants answered indifferently, attributing this result to the Phase 2 nature of the trial and stated that Altimmune was hoping for better results following the Phase 3 trial. Following this news, the price of Altimmune’s common stock declined dramatically. From a closing market price of $7.71 per share on June 25, 2025, Altimmune’s stock price fell to $3.61 per share on June 26, 2025, a decline of 53.2% in the span of just a single day.

Class Period

8/10/23 - 6/25/25

Deadline

October 6 2025

Learn More

26

Days Left

KLC

KinderCare Learning Companies, Inc.

Deadline

October 14 2025

Class Period

This lawsuit is on behalf of all purchasers of KinderCare common stock in or traceable to the Company’s October 2024 initial public offering

Allegations

(a) numerous incidents of child abuse, neglect, and harm had occurred at KinderCare facilities; (b) KinderCare did not provide the “highest quality care possible” at its facilities, and, indeed, in numerous instances had failed to provide even basic care, meet minimum standards in the child care industry, or comply with the laws and regulations governing the care of children; and (c) as a result of (a)-(b) above, KinderCare was exposed to a material, undisclosed risk of lawsuits, adverse regulatory action, negative publicity, reputational damage, and business loss.

Class Period

This lawsuit is on behalf of all purchasers of KinderCare common stock in or traceable to the Company’s October 2024 initial public offering

Deadline

October 14 2025

Learn More

26

Days Left

UNCY

Unicycive Therapeutics, Inc.

Deadline

October 14 2025

Class Period

3/29/24 - 6/27/25

Allegations

(i) Unicycive’s readiness and ability to satisfy the FDA’s manufacturing compliance requirements was overstated; (ii) the oxylanthanum carbonate new drug application’s regulatory prospects were likewise overstated; and (iii) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

3/29/24 - 6/27/25

Deadline

October 14 2025

Learn More

26

Days Left

CHTR

Charter Communications, Inc.

Deadline

October 14 2025

Class Period

This lawsuit is on behalf of all persons and entities who purchased or otherwise acquired Charter securities, purchased call options on Charter common stock, or sold put options on Charter common stock, between July 26, 2024, and July 24, 2025, inclusive.

Allegations

(i) the impact of the Affordable Connectivity Program (ACP) end was a material event the Company was unable to manage or promptly move beyond; (ii) the ACP end was actually having a sustaining impact on Internet customer declines and revenue; (iii) neither was the Company executing broader operations in a way that would compensate for, or overcome the impact, of the ACP ending; (iv) the Internet customer declines and broader failure of Charter’s execution strategy created much greater risks on business plans and earnings growth than reported; (v) accordingly, the Company had no reasonable basis to state the Company was successfully executing operations, managing causes of Internet customer declines, or provide overly optimistic statements about the long term trajectory of the Company and EBITDA growth; and (iv) as a result of the foregoing, defendants materially misled with, and/or lacked a reasonable basis for, their positive statements about the Company’s business, operations, outlook during the Class Period.

Class Period

This lawsuit is on behalf of all persons and entities who purchased or otherwise acquired Charter securities, purchased call options on Charter common stock, or sold put options on Charter common stock, between July 26, 2024, and July 24, 2025, inclusive.

Deadline

October 14 2025

Learn More

32

Days Left

SNAP

Snap Inc.

Deadline

October 20 2025

Class Period

4/29/25 - 8/5/25

Allegations

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Snap’s advertising revenue growth rate; notably, that, due to Snap’s own execution failure, it had significantly declined from 9% in the first quarter to only 1% in April. On August 5, 2025, Snap announced its financial results for the second quarter of fiscal 2025, disclosing a deceleration in advertising revenue growth. The Company attributed the slowdown to “an issue related to our ad platform, the timing of Ramadan and the effects of the de minimis changes.” Following this news, the price of Snap’s common stock declined dramatically. From a closing market price of $9.39 per share on August 5, 2025, Snap’s stock price fell to $7.78 per share on August 6, 2025, a decline of about 17.15% in the span of just a single day.

Class Period

4/29/25 - 8/5/25

Deadline

October 20 2025

Learn More

32

Days Left

PUBM

PubMatic, Inc.

Deadline

October 20 2025

Class Period

2/27/25 - 8/11/25

Allegations

(1) a top demand side platform buyer was shifting a significant number of clients to a new platform which evaluated inventory differently; (2) as a result, PubMatic was seeing a reduction in ad spend and revenue from this top demand side platform buyer; and (3) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

2/27/25 - 8/11/25

Deadline

October 20 2025

Learn More

33

Days Left

AI

C3.ai, Inc.

Deadline

October 21 2025

Class Period

2/26/25 - 8/8/25

Allegations

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of C3 AI’s growth; notably, that its Chief Executive Officer health was having a significant impact on the Company’s ability to close deals, that its management was unable or otherwise ineffectual in minimizing that impact, and that C3 AI would not be able to execute upon its profit and growth potential as a result. On August 8, 2025, C3 AI announced disappointing preliminary financial results for the first quarter of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026. The Company attributed its poor sales results and lowered guidance on “the reorganization with new leadership” and the health ailments of its Chief Executive Officer. Following this news, the price of C3 AI’s common stock declined dramatically. From a closing market price of $22.13 per share on August 8, 2025, C3 AI’s stock price fell to $16.47 per share on August 11, 2025, a decline of about 25.58% in the span of just a single day.

Class Period

2/26/25 - 8/8/25

Deadline

October 21 2025

Learn More

33

Days Left

NUTX

Nutex Health Inc.

Deadline

October 21 2025

Class Period

8/8/24 - 8/14/25

Allegations

(i) HaloMD, a third-party IDR vendor, was achieving lucrative arbitration results for Nutex by engaging in a coordinated scheme to defraud insurance companies; (ii) as a result, to the extent that they were the product of fraudulent conduct, revenues attributable to the Company’s engagement with HaloMD in the IDR process were unsustainable; (iii) in addition, the Company overstated the extent to which it had remediated, and/or its ability to remediate, the material weaknesses in its internal controls over financial reporting; (iv) as a result, the Company was unable to effectively account for the treatment of certain of its stock based compensation obligations; (v) as a result, Nutex improperly calculated these stock based compensation obligations as equity rather than liabilities; (vi) the foregoing increased the risk that the Company would be unable to timely file certain financial reports with the SEC; (vii) accordingly, Nutex’s business and/or financial prospects were overstated; and (viii) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

8/8/24 - 8/14/25

Deadline

October 21 2025

Learn More

37

Days Left

LFMD

LifeMD, Inc.

Deadline

October 25 2025

Class Period

5/7/25 - 8/5/25

Allegations

(1) defendants materially overstated LifeMD’s competitive position; (2) defendants were reckless in raising LifeMD’s 2025 guidance, considering that they had not properly accounted for rising customer acquisition costs in LifeMD’s RexMD segment, as well as for customer acquisition costs related to the sale of drugs designed to treat obesity, including Wegovy and Zepbound; and (3) as a result, defendants’ statements about LifeMD’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

5/7/25 - 8/5/25

Deadline

October 25 2025

Learn More

40

Days Left

DOW

Dow Inc.

Deadline

October 28 2025

Class Period

1/30/25 - 7/23/25

Allegations

(i) Dow’s ability to mitigate macroeconomic and tariff-related headwinds, as well as to maintain the financial flexibility needed to support its lucrative dividend, was overstated; (ii) the true scope and severity of the foregoing headwinds’ negative impacts on Dow’s business and financial condition was understated, particularly with respect to competitive and pricing pressures, softening global sales and demand for the Company’s products, and an oversupply of products in the Company’s global markets; and (iii) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

1/30/25 - 7/23/25

Deadline

October 28 2025

Learn More

40

Days Left

SMLR

Semler Scientific, Inc.

Deadline

October 28 2025

Class Period

3/10/21 - 4/15/25

Allegations

(1) Semler Scientific did not disclose a material investigation by the United States Department of Justice into violations of the False Claims Act, while discussing possible violations of the False Claims Act in hypothetical terms; and (2) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.

Class Period

3/10/21 - 4/15/25

Deadline

October 28 2025

Learn More

46

Days Left

TROX

Tronox Holdings plc

Deadline

November 3 2025

Class Period

2/12/25 - 7/30/25

Allegations

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Tronox’s ability to forecast the demand for its pigment and zircon products or otherwise the true state of its commercial division, despite making lofty long-term projections, Tronox’s forecasting processes fell short as sales continued to decline and costs increased, ultimately, derailing the Company’s revenue projections. On July 30, 2025, Tronox announced its financial results for the second quarter of fiscal 2025, revealing a significant reduction in TiO2 sales for the quarter. The Company attributed the decline to “softer than anticipated coatings season and heightened competitive dynamics.” As a result of the setback in sales, defendants revised the Company’s 2025 financial outlook lowering its full-year revenue guidance and reducing its dividend by 60%. Following this news, Tronox’s common stock declined dramatically. From a closing market price of $5.14 per share on July 30, 2025, Tronox’s stock price fell to $3.19 per share on July 31, 2025, a decline of about 38% in the span of just a single day.

Class Period

2/12/25 - 7/30/25

Deadline

November 3 2025

Learn More

50

Days Left

SVRA

Savara Inc.

Deadline

November 7 2025

Class Period

3/4/24 - 5/23/25

Allegations

(i) MOLBREEVI BLA, the treatment of pulmonary alveolar proteinosis, lacked sufficient information regarding MOLBREEVI’s chemistry, manufacturing, and/or controls; (ii) accordingly, FDA was unlikely to approve the MOLBREEVI BLA in its current form; (iii) foregoing made it unlikely that Savara would complete its submission of the MOLBREEVI BLA within the timeframe it had represented to investors; (iv) delay in MOLBREEVI’s regulatory approval increased the likelihood that the Company would need to raise additional capital; and (v) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

3/4/24 - 5/23/25

Deadline

November 7 2025

Learn More

53

Days Left

LNTH

Lantheus Holdings, Inc.

Deadline

November 10 2025

Class Period

2/26/25 - 8/5/25

Allegations

According to the filed complaint, defendants made false statements and/or concealed that: defendants created the false impression that they possessed reliable information pertaining to the Company’s projected revenue outlook and anticipated growth while also minimizing risk from competition and pricing dynamics, seasonality, and macroeconomic fluctuations. In truth, Lantheus’ optimistic reports of Pylarify’s sales growth potential and pricing normalization fell short of reality; Lantheus, despite defendants claims, did not have an accurate understanding of the pricing and competitive dynamics of Pylarify’s market.

Class Period

2/26/25 - 8/5/25

Deadline

November 10 2025

Learn More

53

Days Left

FLYE

Fly-E Group, Inc.

Deadline

November 10 2025

Class Period

7/15/25 - 8/14/25

Allegations

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the safety of Fly-E’s lithium battery which in turn took a material toll on its E-vehicle sales revenue, despite making lofty long-term projections, Fly-E’s forecasting processes fell short as sales continued to decline and operating expenses increased, ultimately, derailing the Company’s revenue projections. On August 14, 2025, the truth emerged when Fly-E filed a form NT 10-Q: Notification of inability to timely file Form 10-Q for the first quarter of fiscal year 2026 revealing a substantial decrease of 32% in net revenues “primarily driven by a decrease in total units sold.” In pertinent part, the Company attributed the decline to “recent lithium-battery accidents involving E-Bikes and E-Scooters.” Following this news, the price of Fly E’s common stock declined dramatically. From a closing market price of $7.76 per share on August 14, 2025, Fly-E’s stock price fell to $1.00 per share on August 15, 2025, a decline of about 87% in the span of just a single day.

Class Period

7/15/25 - 8/14/25

Deadline

November 10 2025

Learn More

55

Days Left

VFC

V.F. Corporation

Deadline

November 12 2025

Class Period

10/30/23 - 5/20/25

Allegations

According to the complaint, defendants disseminated materially false and misleading statements and/or concealed material adverse facts concerning the true state of VFC’s turnaround plans; notably, that additional significant reset actions would be necessary to return the Vans brand to growth, resulting in significant setbacks to Vans’ revenue growth trajectory. The truth emerged on May 21, 2025, when VFC reported its fourth quarter and full-year fiscal 2025 results, highlighting a significant decline in Vans’ growth trajectory, which faltered from an 8% loss the quarter before to a 20% loss in the fourth quarter, and noting such decline would continue through the next quarter. The Company attributed its results and below-expectation guidance largely as “a direct effect of deliberately reduced revenue to eliminate unprofitable or unproductive businesses” and “an additional set of deliberate actions” already in-place but previously unannounced. VFC further noted that, disregarding these deliberate actions, Vans would still have shown a “high single digit[]” revenue decline, suggesting growth slowed in comparison to the prior years’ sequential improvements irrespective of management’s new “deliberate actions.” On this news, the price of VFC’s common stock declined dramatically. From a closing market price of $14.43 per share on May 20, 2025, VFC’s stock price fell to $12.15 per share on May 21, 2025, a decline of about 15.8% in the span of just a single day.

Class Period

10/30/23 - 5/20/25

Deadline

November 12 2025

Learn More

60

Days Left

CYTK

Cytokinetics, Incorporated

Deadline

November 17 2025

Class Period

12/27/23 - 5/6/25

Allegations

According to the complaint, defendants made materially false and misleading statements regarding the timeline for the New Drug Application (“NDA”) submission and approval process for aficamten. Specifically, defendants represented that the Company expected approval from the U.S. Food and Drug Administration (“FDA”) for its NDA for aficamten in the second half of 2025, based on a September 26, 2025 PDUFA date, and failed to disclose material risks related to the Company’s failure to submit a Risk Evaluation and Mitigation Strategy (“REMS”) that could delay the regulatory process. On May 6, 2025, during an earnings call, it was revealed that the Company had multiple pre-NDA meetings with the FDA discussing safety monitoring and risk mitigation but chose to submit the NDA without a REMS, relying on labeling and voluntary education materials. This confirmed defendants’ awareness of potential REMS requirements and their reckless decision to omit it from the initial submission, misleading investors about the regulatory timeline. As a result of defendants’ false and misleading statements, class members purchased Cytokinetics’ common stock at artificially inflated prices and suffered significant losses when the truth was revealed.

Class Period

12/27/23 - 5/6/25

Deadline

November 17 2025

Learn More

Never Miss a Potential Recovery Again

Sign up for Class Action Alerts

$723,900,000 in Total Settlement Funds Available. See if you qualify!Find Out More

We Give Shareholders A Voice.

Settlements

Who We Are

Find an Attorney

Find a Case

Upcoming Deadlines

ANRO

Alto Neuroscience, Inc.

REPL

Replimune Group, Inc.

FI

Fiserv, Inc.

News

CAPR Stock Tanks After FDA Rejection—Investors Sue

NEOG Investors Sue After Merger Goes Rotten

Levi & Korsinsky Appointed Lead Counsel in VSTS Case

Our World-Class Team

Sign up for Class
Action Alerts